EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Human Immunodeficiency Virus Type 1 Risk Assessment Tool for Women Aged 15–49 Years in African Countries: A Pooled Analysis Across 15 Nationally Representative Surveys

Nora E Rosenberg iD, Bonnie E Shook-Sa iD, Amber M Young, Yating Zou iD, Lynda Stranix-Chibanda iD, Marcel Yotebieng iD, Nadia A Sam-Agudu, Sam J Phiri, Wilbroad Mutale iD, Linda-Gail Bekker iD, Manhattan E Charurat iD, Sizulu Moyo iD und 4 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Nora E Rosenberg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cepheid, NIAID NIH HHS, FHERA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Women in Africa disproportionately acquire human immunodeficiency virus type 1 (HIV-1). Understanding which women are most likely to acquire HIV-1 can guide focused prevention with preexposure prophylaxis (PrEP). Our objective was to identify women at the highest risk of HIV-1 and estimate PrEP efficiency at different sensitivity levels.

Methods

Nationally representative data were collected from 2015 through 2019 from 15 population-based household surveys. This analysis included women aged 15–49 who tested HIV-1 seronegative or had recent HIV-1. Least absolute shrinkage and selection operator regression models were fit with 28 variables to predict recent HIV-1. Models were trained on the full population and internally cross-validated. Performance was evaluated using area under the receiver operating characteristic curve (AUC), sensitivity, and number needed to treat (NNT) with PrEP to avert 1 infection.

Results

Among 209 012 participants, 248 had recent HIV-1 infection, representing 118 million women and 402 000 (95% confidence interval [CI], 309 000–495 000) annual infections. Two variables were retained: living in a subnational area with high HIV-1 viremia and having a sexual partner living outside the home. The full-population AUC was 0.80 (95% CI, .76–.84); cross-validated AUC was 0.79 (95% CI, .75–.84). At 33% sensitivity, 130 000 cases could be averted if 7.9 million women were perfectly adherent to PrEP; NNT would be 61. At 67% sensitivity, 260 000 cases could be averted if 25.1 million women were perfectly adherent; NNT would be 96.

Conclusions

This risk assessment tool was generalizable, predictive, and parsimonious with trade-offs between reach and efficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Pre-Exposure ProphylaxisHumansFemaleAdolescentAdultYoung AdultRisk AssessmentMiddle AgedAfricaSurveys and QuestionnairesAnti-HIV AgentsRisk Factors

Stichwörter der Autor:innen

AfricaHIVpreexposure prophylaxispreventionrisk

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Child and Adolescent Health Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
  • University of Zimbabwe Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
  • Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Global Pediatrics Program and Division of Infectious Diseases, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

ORCID-Profile: Nora E Rosenberg, Bonnie E Shook-Sa, Yating Zou, Lynda Stranix-Chibanda, Marcel Yotebieng, Wilbroad Mutale, Linda-Gail Bekker, Manhattan E Charurat, Sizulu Moyo, Khangelani Zuma, Jessica Justman, Michael G Hudgens, Benjamin H Chi

Förderung

  • Cepheid
  • NIAID NIH HHS
  • FHERA
  • NIMH NIH HHS
  • Novartis
  • FIC NIH HHS
  • CGH CDC HHS
  • NHLBI NIH HHS

Zitieren

APA

Rosenberg, N. E., Shook-Sa, B. E., Young, A. M., Zou, Y., Stranix-Chibanda, L., Yotebieng, M., Sam-Agudu, N. A., Phiri, S. J., Mutale, W., Bekker, L. G., Charurat, M. E., Moyo, S., Zuma, K., Justman, J., Hudgens, M. G., & Chi, B. H. (2024). A Human Immunodeficiency Virus Type 1 Risk Assessment Tool for Women Aged 15–49 Years in African Countries: A Pooled Analysis Across 15 Nationally Representative Surveys. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae211

Vancouver

Rosenberg NE, Shook-Sa BE, Young AM, Zou Y, Stranix-Chibanda L, Yotebieng M, et al. A Human Immunodeficiency Virus Type 1 Risk Assessment Tool for Women Aged 15–49 Years in African Countries: A Pooled Analysis Across 15 Nationally Representative Surveys. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae211

BibTeX
@article{Rosenberg2024,
  author = {Rosenberg, Nora E and Shook-Sa, Bonnie E and Young, Amber M and Zou, Yating and Stranix-Chibanda, Lynda and Yotebieng, Marcel and Sam-Agudu, Nadia A and Phiri, Sam J and Mutale, Wilbroad and Bekker, Linda-Gail and Charurat, Manhattan E and Moyo, Sizulu and Zuma, Khangelani and Justman, Jessica and Hudgens, Michael G and Chi, Benjamin H},
  title = {A Human Immunodeficiency Virus Type 1 Risk Assessment Tool for Women Aged 15–49 Years in African Countries: A Pooled Analysis Across 15 Nationally Representative Surveys},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae211}
}
Kostenlos starten →